Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Meeting ReportPoster Presentations - Physicians/Scientists/Pharmacists

Dual time point FDG-PET-CT imaging in differentiating benign from malignant lung nodules: Our experience in 119 patients

Francesco Giacomuzzi, Faustino Bonutti, Maurizio Rocco, Aldo Modesto, Fernando Di Gregorio, Michele Povolato, Angelo Morelli, Ornella Belvedere, Francesco Pessina and Onelio Geatti
Journal of Nuclear Medicine May 2006, 47 (suppl 1) 472P;
Francesco Giacomuzzi
1Nuclear Medicine, Azienda Ospedaliera S.M. della MIsericordia, Udine, Udine, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Faustino Bonutti
2Physics, Azienda Ospedaliera S.M. della Misericordia, Udine, Udine, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maurizio Rocco
3Pathology, Azienda Ospedaliera S.M. della Misericordia, Udine, Udine, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aldo Modesto
5Radiology, Azienda Ospedaliera S.M. della Misericordia, Udine, Udine, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fernando Di Gregorio
1Nuclear Medicine, Azienda Ospedaliera S.M. della MIsericordia, Udine, Udine, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michele Povolato
1Nuclear Medicine, Azienda Ospedaliera S.M. della MIsericordia, Udine, Udine, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angelo Morelli
4Thoracic Surgery, Azienda Ospedaliera S.M. della Misericordia, Udine, Udine, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ornella Belvedere
7Oncology, Azienda Ospedaliera S.M. della Misericordia, Udine, Udine, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesco Pessina
5Radiology, Azienda Ospedaliera S.M. della Misericordia, Udine, Udine, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Onelio Geatti
1Nuclear Medicine, Azienda Ospedaliera S.M. della MIsericordia, Udine, Udine, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1745

Objectives: To assay the usefulness of dual time (1 and 2 hours) 18F-FDG-PET-CT acquisition imaging, in evaluating newly diagnosed lung lesions incidentally discovered and compare with the standard technique.

Methods: In 119 patients (of whom 23 with multiple nodules; 85 m, 34 f; m.a. 67 y), we calculated early and delayed SUV. Final diagnosis was based on histology for patients with a positive PET-CT, while in case of a negative scan, we assumed this correspond to a benign disease if serial CT studies had not demonstrated any progression and patients were free of malignancies at 12 months follow-up.

Results: 54 patients had malignant tumours and 65, benign diseases. Tumour max-SUVs were 7.9 ± 4.7 and 10.4 ± 5.8 at 1 and 2 h respectively, with a mean increase rate of 34.8% ± 26.9% (p < 0.001). Benign lesions had max-SUVs of 1.8 ± 1.3 and 1.8 ± 1.9, with not significant decrease over time (-4.2% ± 20.5%). An early maxSUV threshold of 2.5 accurately differentiated malignancies from benign diseases (sens 91% and spec 83%). Dual time acquisition allows better lesion characterization and evaluating the differential gradient increase, improves accuracy. Even better results are yielded if different cut off values are chosen in case of lesions with early high or low uptake: when early SUV>2.5, a further increase as low as 10% is highly predictive of malignancy, but in low gradient lesions (SUV<2.5), the increase must be higher than 40% to be significant. In this way we got sensitivity and specificity of 96% and 92% respectively. This allowed to correctly identify 6 patients with chronic inflammations, who although had a relatively high early SUV, did not show a further increase at the 2nd hour and three low grade malignant nodules (1 well-differentiated adenocarcinoma, 1 well-differentiated squamous carcinoma, 1 lymphoma), which had an early low SUV, but a > 40% SUV increase by the 2nd hour. We had 2 FN (1 carcinoid and 1 well differentiated adenocarcinoma)and 5 FP (active inflammations or metaplasia).

Conclusions: preliminary data show dual time point imaging FDG-PET-CT with thresholds increase of 10% or 40% if 1h-SUV is higher or lower than 2.5 respectively, improves accuracy (especially for a significant increase of specificity; p< 0.05), in the differential diagnosis of lung lesions.

  • Society of Nuclear Medicine, Inc.
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 47, Issue suppl 1
May 1, 2006
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Dual time point FDG-PET-CT imaging in differentiating benign from malignant lung nodules: Our experience in 119 patients
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Dual time point FDG-PET-CT imaging in differentiating benign from malignant lung nodules: Our experience in 119 patients
Francesco Giacomuzzi, Faustino Bonutti, Maurizio Rocco, Aldo Modesto, Fernando Di Gregorio, Michele Povolato, Angelo Morelli, Ornella Belvedere, Francesco Pessina, Onelio Geatti
Journal of Nuclear Medicine May 2006, 47 (suppl 1) 472P;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Dual time point FDG-PET-CT imaging in differentiating benign from malignant lung nodules: Our experience in 119 patients
Francesco Giacomuzzi, Faustino Bonutti, Maurizio Rocco, Aldo Modesto, Fernando Di Gregorio, Michele Povolato, Angelo Morelli, Ornella Belvedere, Francesco Pessina, Onelio Geatti
Journal of Nuclear Medicine May 2006, 47 (suppl 1) 472P;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Poster Presentations - Physicians/Scientists/Pharmacists

  • Phase I/II study of Yttrium-90 labeled humanized anti-Tac (HAT) monoclonal antibody and calcium DTPA in adult T-cell leukemia/lymphoma (ATL)
  • Limitation of F-18 FDG PET/CT in preoperative nodal staging of squamous cell head and neck cancer
  • Characterization and acute toxicity of alginate hydrogel for combined radiochemotherapy
Show more Poster Presentations - Physicians/Scientists/Pharmacists

Oncology Track

  • Clinical value of radionuclide hepatic arterial infusion pump perfusion scan in detecting extrahepatic perfusion of hepatic arterial infusion pump
  • Experience in patients with pulmonary nodules using the dual-tracer C-11 methionine and F-18 FDG PET studies: Initial results
  • FDG PET-CT in chronic lymphocytic leukemia
Show more Oncology Track

Similar Articles

SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire